Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-08-26, Stock:ABBV, The news for the past five days is as follows:
2020-08-19: NEWS1: 3 Strong, Diverse Dividend Stocks to Buy with Market at New Highs.NEWS2: FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug.NEWS3: Potential Gilead Blockbusters Were Rejected By the FDA. Why That’s the ‘Near-Worst-Case Scenario’ for the Stock..NEWS4: Dow Jones Today, Stocks Mixed; Target Heads Retail Rally; Biotechs Momenta, Gilead, BioMarin Swing Wild On Merger, FDA News.NEWS5: Dow Jones Today, Stocks Open On This Rise; Target Heads Retail Rally; Biotechs Momenta, Gilead, Biomarin Swing Wild On Merger, FDA News.NEWS6: Dow Jones Today, Futures Mixed; Target Heads Retail Rally; Gilead, Biomarin Swoon  As FDA Balks.
2020-08-20: NEWS1: Pfizer’s Covid Vaccine Could Be Authorized Soon. That’s Not the Only Positive News for the Stock..
2020-08-21: nan
2020-08-24: NEWS1: Stay Patient With AbbVie.
2020-08-25: NEWS1: Do AbbVie's (NYSE:ABBV) Earnings Warrant Your Attention?.NEWS2: AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis.NEWS3: The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout.NEWS4: AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases.NEWS5: Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases.

Answer: Rise